Citation Impact
Citing Papers
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
2013 Standout
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Inhibition of angiogenesis by β-galactosylceramidase deficiency in globoid cell leukodystrophy
2013
ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.
2002
Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue
2001
Engineering precision nanoparticles for drug delivery
2020 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
Ultrastructural Characterization of the Lower Motor System in a Mouse Model of Krabbe Disease
2016 Standout
Red flags to screen for malignancy and fracture in patients with low back pain: systematic review
2013
Targeting hypoxia in cancer therapy
2011 Standout
Blood Vessel Tubulogenesis Requires Rasip1 Regulation of GTPase Signaling
2011
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Targeting HIF-1 for cancer therapy
2003 StandoutNobel
Interleukin-12 and the regulation of innate resistance and adaptive immunity
2003 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
2014 Standout
Drug penetration in solid tumours
2006 Standout
Imaging in the era of molecular oncology
2008 StandoutNature
Tumor angiogenesis: past, present and the near future
2000
Malignant astrocytic glioma: genetics, biology, and paths to treatment
2007 Standout
Non-specific low back pain
2016 Standout
TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice
2011
Disrupting tumour blood vessels
2005
Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?
2008
Tumor‐selective Blood Flow Decrease Induced by an Angiotensin Converting Enzyme Inhibitor, Temocapril Hydrochloride
2000
Angiogenesis in cancer and other diseases
2000 StandoutNature
Tumor-Associated Macrophages: From Mechanisms to Therapy
2014 Standout
Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2015
Exploiting tumour hypoxia in cancer treatment
2004 Standout
Assessing responses to cancer therapy using molecular imaging
2006
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF
2003
Role of Hypoxia-Inducible Factor 1 in Gastric Cancer Cell Growth, Angiogenesis, and Vessel Maturation
2004 StandoutNobel
Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts
2006
Advances and Challenges of Liposome Assisted Drug Delivery
2015 Standout
The biology of the combretastatins as tumour vascular targeting agents
2002
The synthesis and tubulin binding activity of thiophene-based analogues of combretastatin A-4
2001
Metabolomics: the apogee of the omics trilogy
2012 Standout
Improvement ofClostridiumtumour targeting vectors evaluated in rat rhabdomyosarcomas
2001
Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial
2005 Standout
Vascular‐targeting therapies for treatment of malignant disease
2004
High-Resolution Microtubule Structures Reveal the Structural Transitions in αβ-Tubulin upon GTP Hydrolysis
2014 StandoutNobel
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Microtubules as a target for anticancer drugs
2004 Standout
Basic and Therapeutic Aspects of Angiogenesis
2011 Standout
The von Hippel–Lindau protein, HIF hydroxylation, and oxygen sensing
2005 StandoutNobel
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
2015
Synthesis and biological evaluation of aryl azide derivatives of combretastatin a-4 as molecular probes for tubulin
2000
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
2000 Standout
Phase II study of pemetrexed in combination with carboplatin in the first‐line treatment of advanced nonsmall cell lung cancer
2005
Modes of resistance to anti-angiogenic therapy
2008 Standout
Organic Azides: An Exploding Diversity of a Unique Class of Compounds
2005 Standout
Angiogenesis as a therapeutic target
2005 StandoutNature
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Tumor Angiogenesis
2008 Standout
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
2017 Standout
A Phase II Trial of Fosbretabulin in Advanced Anaplastic Thyroid Carcinoma and Correlation of Baseline Serum-Soluble Intracellular Adhesion Molecule-1 with Outcome
2009
Photoswitchable anticancer activity via trans–cis isomerization of a combretastatin A-4 analog
2015
SuFEx Click Chemistry Enabled Late-Stage Drug Functionalization
2018 StandoutNobel
Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer
2018 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
From radiotherapy to Targeted therapy: 20 years in the management of non-small-cell lung cancer.
2006
The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer
2004 StandoutNobel
Synthesis of Heterocycles via Electrophilic Cyclization of Alkynes Containing Heteroatom
2011 Standout
Synthesis, Characterization, and Bioactivity of the Photoisomerizable Tubulin Polymerization Inhibitor azo-Combretastatin A4
2015
Synthesis and biological properties of bioreductively targeted nitrothienyl prodrugs of combretastatin A-4
2006
Vascular Targeting Agents as Cancer Therapeutics
2004
Effects of Aging and Hypoxia-Inducible Factor-1 Activity on Angiogenic Cell Mobilization and Recovery of Perfusion After Limb Ischemia
2007 StandoutNobel
Metabolic Imaging by Hyperpolarized 13C Magnetic Resonance Imaging for In vivo Tumor Diagnosis
2006
Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies
2006
Bright Side of Lignin Depolymerization: Toward New Platform Chemicals
2018 Standout
Doppler ultrasound imaging detects changes in tumor perfusion during antivascular therapy associated with vascular anatomic alterations.
2001
Tumour vasculature as a target for anticancer therapy
2000
Discovery of 4-Amino and 4-Hydroxy-1-aroylindoles as Potent Tubulin Polymerization Inhibitors
2008
Nanoparticles in Photodynamic Therapy
2015 Standout
Advances in the Chemistry of Tetrahydroquinolines
2011 Standout
Combretastatin A-4 Analogue: A Dual-Targeting and Tubulin Inhibitor Containing Antitumor Pt(IV) Moiety with a Unique Mode of Action
2016
Inositol Polyphosphate Multikinase Inhibits Angiogenesis via Inositol Pentakisphosphate-Induced HIF-1α Degradation
2017 StandoutNobel
Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability.
2001
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
2006 Standout
Advances in Copper Complexes as Anticancer Agents
2013 Standout
Emerging Targets in Photopharmacology
2016 StandoutNobel
Concept and Clinical Evaluation of Carrier-Mediated Anticancer Agents
2008
The tumor vascular targeting agent combretastatin A–4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells
2002
Genes Expressed in Human Tumor Endothelium
2000 StandoutScience
Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance
2012
Cytotoxic activities and metabolic studies of new combretastatin analogues
2015
Works of G. Dark being referenced
A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1)
2006
Randomized Trial of Two Intravenous Schedules of the Topoisomerase I Inhibitor Liposomal Lurtotecan in Women With Relapsed Epithelial Ovarian Cancer: A Trial of the National Cancer Institute of Canada Clinical Trials Group
2005
Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer.
2010
Proven bioequivalence of blood exposure between vinorelbine 80 mg/m2 oral and 30 mg/m2 IV doses in cancer patients
2005
Combretastatin A-4, an agent that displays selective toxicity towards tumour vasculature
1997
Pemetrexed Combined with Oxaliplatin or Carboplatin as First-Line Treatment in Advanced Non–Small Cell Lung Cancer: A Multicenter, Randomized, Phase II Trial
2005
Differentiation and Definition of Vascular-Targeted Therapies
2005
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
1997